ArticleJournal of the Endocrine Society2025

LUMIADE 3: Therapeutic Equivalence of Denosumab Biosimilar FKS518 to Reference Product in Postmenopausal Osteoporosis.

Ewa Krecipro-Nizinska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.